Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Shelton Capital Management

Shelton Capital Management decreased its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 79.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,672 shares of the company's stock after selling 46,312 shares during the quarter. Shelton Capital Management's holdings in Moderna were worth $485,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB raised its holdings in Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after acquiring an additional 587 shares during the last quarter. Compass Planning Associates Inc bought a new position in shares of Moderna during the fourth quarter valued at $37,000. Venturi Wealth Management LLC lifted its holdings in shares of Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after purchasing an additional 664 shares in the last quarter. Crowley Wealth Management Inc. purchased a new stake in shares of Moderna during the fourth quarter valued at $41,000. Finally, MassMutual Private Wealth & Trust FSB increased its holdings in Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock worth $44,000 after buying an additional 389 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Stock Performance

NASDAQ:MRNA traded down $0.84 during mid-day trading on Tuesday, hitting $25.96. 2,009,965 shares of the company's stock traded hands, compared to its average volume of 7,177,103. The company has a fifty day moving average of $31.40 and a 200 day moving average of $40.57. The company has a market capitalization of $10.04 billion, a P/E ratio of -2.80 and a beta of 2.23. Moderna, Inc. has a twelve month low of $23.15 and a twelve month high of $170.47.

Analyst Ratings Changes

MRNA has been the subject of several research reports. Citigroup initiated coverage on shares of Moderna in a report on Thursday, March 13th. They set a "neutral" rating and a $40.00 price objective for the company. Royal Bank of Canada reissued a "sector perform" rating and set a $40.00 price objective on shares of Moderna in a research report on Tuesday, February 18th. Berenberg Bank lifted their target price on Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a research report on Thursday, January 16th. Bank of America decreased their price objective on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research note on Tuesday, February 11th. Finally, UBS Group decreased their target price on shares of Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a research note on Wednesday, February 19th. Four investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $58.70.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.